BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 29575535)

  • 1. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
    Miao J; Kyoyama H; Liu L; Chan G; Wang Y; Urisman A; Yang YL; Liu S; Xu Z; Bin H; Li H; Jablons DM; You L
    J Cell Mol Med; 2020 Jan; 24(1):1087-1098. PubMed ID: 31755214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting YAP in malignant pleural mesothelioma.
    Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
    J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
    PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
    Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
    Hsu PC; Yang CT; Jablons DM; You L
    Biomedicines; 2018 Dec; 6(4):. PubMed ID: 30544524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Yasufuku K
    Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
    Zhang S; Yang YL; Wang Y; You B; Dai Y; Chan G; Hsieh D; Kim IJ; Fang LT; Au A; Stoppler HJ; Xu Z; Jablons DM; You L
    J Exp Clin Cancer Res; 2014 Nov; 33(1):93. PubMed ID: 25422081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
    Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH
    Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
    Maille E; Levallet J; Dubois F; Antoine M; Danel C; Creveuil C; Mazieres J; Margery J; Greillier L; Gounant V; Moro-Sibilot D; Molinier O; Léna H; Monnet I; Bergot E; Langlais A; Morin F; Scherpereel A; Zalcman G; Levallet G
    Int J Cancer; 2022 Jun; 150(11):1889-1904. PubMed ID: 35262190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.